세계의 유리체내(IVT) 주사제 시장 : 제품 유형별, 최종 사용자별, 지역별 - 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has conducted a thorough analysis of the Intravitreal (IVT) Injectable Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Intravitreal (IVT) Injectable Market spanning from 2024 to 2031.

Intravitreal injections offer a safe and effective treatment for retinal diseases like diabetic retinopathy and macular degeneration. The global market for these injections is expected to reach $21613.04 million by 2031, with a strong CAGR of 4.9%.

Key Insights:

• Intravitreal (IVT) Injectable Market Size (2024): US$19641.06 Mn
• Projected Market Value (2031): US$ 21613.04 Mn
• Global Market Growth Rate (CAGR 2024 - 2031): 4.9%

Intravitreal (IVT) Injectable Market - Report Scope

The scope of the Intravitreal (IVT) Injectable Market report encompasses a comprehensive analysis of various factors shaping the industry landscape. This includes segmentation based on product types, application areas, end-user industries, and geographical regions. The report covers market size, historical trends, current market dynamics, and future growth prospects within the specified timeframe. Additionally, it examines key market drivers, challenges, opportunities, and regulatory factors influencing market growth. Competitive landscape analysis, including profiles of major players, market share analysis, and strategic initiatives, is also included.

Furthermore, the report provides insights into emerging trends, technological advancements, and investment opportunities in the Intravitreal (IVT) Injectable Market. Overall, the report aims to provide stakeholders with valuable insights to make informed decisions and capitalize on opportunities in the global Intravitreal (IVT) Injectable Market.

Market Growth Drivers

The growth of the Intravitreal (IVT) Injectable Market is driven by several key factors. Firstly, the increasing prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases is driving the demand for intravitreal injectable therapies as effective treatment options. Additionally, advancements in drug delivery technologies and the development of novel therapeutic agents have expanded the treatment options available for intravitreal injections, further fueling market growth. Furthermore, the growing elderly population, particularly in developed regions, is contributing to the rising incidence of retinal diseases, thereby boosting the demand for intravitreal injectable treatments.

Moreover, the expanding indications for intravitreal injections beyond AMD and diabetic retinopathy, such as macular edema, retinal vein occlusion, and uveitis, are widening the market opportunities for intravitreal injectable manufacturers. Additionally, the increasing adoption of intravitreal injections as first-line treatments for certain retinal conditions, owing to their efficacy and minimally invasive nature, is driving market growth. Furthermore, the growing awareness about the importance of early detection and treatment of retinal diseases among both patients and healthcare professionals is expected to further drive market expansion in the coming years.

Market Restraints

Despite its promising growth prospects, the Intravitreal (IVT) Injectable Market faces certain restraints that may hinder its expansion. One significant challenge is the high cost associated with intravitreal injections and related treatment regimens, which can limit patient access to therapy, particularly in regions with limited healthcare resources. Additionally, reimbursement challenges and pricing pressures from payers may impact market growth by affecting the affordability and accessibility of intravitreal injectable treatments for patients.

Moreover, safety concerns related to intravitreal injections, such as the risk of ocular complications like retinal detachment, endophthalmitis, and intraocular pressure elevation, may deter patients and healthcare providers from opting for these treatments. Furthermore, the requirement for frequent injections and the potential for treatment burden, including the need for regular monitoring and follow-up visits, may affect patient compliance and adherence to therapy, thereby impacting market growth. Additionally, the COVID-19 pandemic has disrupted healthcare systems and patient access to elective procedures, leading to a temporary slowdown in market growth.

Opportunities

The Intravitreal (IVT) Injectable Market presents several opportunities for growth and innovation. Firstly, the increasing adoption of intravitreal injections as a standard of care for various retinal diseases presents a significant opportunity for manufacturers to develop targeted therapies with improved efficacy and safety profiles. Additionally, advancements in drug delivery technologies, such as sustained-release implants and biodegradable microspheres, offer opportunities to enhance the duration of action and reduce the frequency of injections, thereby improving patient convenience and compliance.

Moreover, the growing emphasis on personalized medicine and precision therapeutics presents opportunities to develop tailored intravitreal injectable treatments based on genetic and molecular biomarkers, thereby optimizing treatment outcomes and minimizing side effects. Furthermore, expanding indications for intravitreal injections in other ophthalmic conditions, such as glaucoma and ocular inflammation, offer avenues for market expansion and diversification. Lastly, collaborations between industry players, academic institutions, and research organizations are expected to drive innovation and accelerate the development of novel intravitreal injectable therapies. Capitalizing on these opportunities will be crucial for companies operating in the Intravitreal (IVT) Injectable Market to maintain a competitive edge and sustain long-term growth.

Key Questions Answered in Report::

• What is the current market size of the Intravitreal (IVT) Injectable Market, and what is its projected growth trajectory?
• What factors are driving the demand for intravitreal injectable therapies?
• What are the major challenges and restraints faced by the Intravitreal (IVT) Injectable Market?
• What opportunities exist for growth and innovation within the Intravitreal (IVT) Injectable Market?
• Who are the key players in the market, and how is the competitive landscape structured?

Competitive Intelligence and Business Strategy

Competitive intelligence plays a vital role in shaping effective business strategies within the Bone Void Fillers Market. By closely monitoring competitors' actions, such as product launches, pricing strategies, and market expansions, companies can gain valuable insights into market trends and customer preferences. This information enables them to identify competitive advantages and capitalize on market opportunities.

Furthermore, understanding the competitive landscape allows companies to refine their business strategies and differentiate their offerings from competitors. For example, identifying unmet needs or underserved market segments can guide product development efforts and inform targeted marketing campaigns to gain a competitive edge.

Moreover, competitive intelligence helps companies anticipate and respond to market dynamics, such as regulatory changes or technological advancements, proactively. By staying ahead of the curve, companies can adapt their strategies quickly to maintain relevance and drive growth in the face of evolving market conditions.

Key Companies Profiled

• Regeneron Pharmaceuticals, Inc.
• Bausch & Lomb
• Novartis AG
• Allergan
• Alimera Sciences
• ThromboGenics, Inc.
• Bristol-Myers Squibb Company

Intravitreal (IVT) Injectable Market Categorization

Intravitreal (IVT) Injectable Market by Indication

• Macular Degeneration
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Endophthalmitis
• Others

Intravitreal (IVT) Injectable Market by Drug Class

• Anti-VEGF
• Corticosteroids
• Antibiotics
• Antivirals
• Antifungals

Intravitreal (IVT) Injectable Market by Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Market Overview
• 1.2. Market Analysis
• 1.3. PMR Analysis and Recommendations

2. Market Introduction

• 2.1. Market Taxonomy
• 2.2. Market Definition

3. Key Inclusions and Exclusions

4. Market Opportunity Analysis

• 4.1. Macro-Economic Factors
• 4.2. Opportunity Analysis

5. Market Dynamics

• 5.1. Drivers
  • 5.1.1. Supply Side Drivers
  • 5.1.2. Demand Side Drivers
• 5.2. Restraints
• 5.3. Trends

6. Epidemiology Analysis

7. Reimbursement Guidelines

8. Pipeline Analysis

9. Global Economic Outlook

• 9.1. Gross Domestic Indication Type by Region & Country, 2006 - 2023
• 9.2. Global Healthcare Market Indicators

10. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2032, by Drug Class

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) By Drug Class, 2019-2023
  • 10.2.1. Anti-VEGF
  • 10.2.2. Corticosteroids
  • 10.2.3. Antibiotics
  • 10.2.4. Antivirals
  • 10.2.5. Antifungals
• 10.3. Market Size (US$ Mn) Forecast By Drug Class, 2024-2032
• 10.4. Market Attractiveness Analysis By Drug Class

11. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2032, by Indication

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) By Indication, 2019-2023
  • 11.2.1. Diabetic Retinopathy
  • 11.2.2. Macular Degeneration
  • 11.2.3. Endophthalmitis
  • 11.2.4. Retinal Vein Occlusions
  • 11.2.5. Others
• 11.3. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 11.4. Market Attractiveness Analysis By Indication

12. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031, by Distributional Channel

• 12.1. Introduction / Key Findings
• 12.2. Historical Market Size (US$ Mn) By Distributional Channel, 2019-2023
  • 12.2.1. Hospital Pharmacies
  • 12.2.2. Retail Pharmacies
  • 12.2.3. Drug Stores
  • 12.2.4. Mail Order Pharmacies
  • 12.2.5. Others
• 12.3. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 12.4. Market Attractiveness Analysis By Distributional Channel

13. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) By Region, 2019-2023
  • 13.2.1. North America
  • 13.2.2. Latin America
  • 13.2.3. Europe
  • 13.2.4. South Asia
  • 13.2.5. East Asia
  • 13.2.6. Oceania
  • 13.2.7. Middle East and Africa
  • 13.2.8. Emerging Countries
• 13.3. Market Size (US$ Mn) Forecast By Region, 2024-2031
• 13.4. Market Attractiveness Analysis By Region

14. North America Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) and By Country, 2019-2023
  • 14.2.1. U.S.
  • 14.2.2. Canada
• 14.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 14.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 14.4.1. Anti-VEGF
  • 14.4.2. Corticosteriods
  • 14.4.3. Antibiotics
  • 14.4.4. Antivirals
  • 14.4.5. Antifungals
• 14.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 14.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 14.6.1. Diabetic Retinopathy
  • 14.6.2. Macular Degeneration
  • 14.6.3. Endophthalmitis
  • 14.6.4. Retinal Vein Occlusion
  • 14.6.5. Others
• 14.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 14.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 14.8.1. Hospital Pharmacies
  • 14.8.2. Retail Pharmacies
  • 14.8.3. Drug Stores
  • 14.8.4. Mail Order Pharmacies
  • 14.8.5. Others
• 14.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 14.10. Market Attractiveness Analysis
  • 14.10.1. By Country
  • 14.10.2. By Drug Class
  • 14.10.3. By Indication
  • 14.10.4. By Distributional Channel
• 14.11. Drivers and Restraints: Impact Analysis

15. Latin America Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
  • 15.2.1. Brazil
  • 15.2.2. Mexico
  • 15.2.3. Rest of Latin America
• 15.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 15.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 15.4.1. Anti-VEGF
  • 15.4.2. Corticosteriods
  • 15.4.3. Antibiotics
  • 15.4.4. Antivirals
  • 15.4.5. Antifungals
• 15.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 15.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 15.6.1. Diabetic Retinopathy
  • 15.6.2. Macular Degeneration
  • 15.6.3. Endophthalmitis
  • 15.6.4. Retinal Vein Occlusion
  • 15.6.5. Others
• 15.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 15.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 15.8.1. Hospital Pharmacies
  • 15.8.2. Retail Pharmacies
  • 15.8.3. Drug Stores
  • 15.8.4. Mail Order Pharmacies
  • 15.8.5. Others
• 15.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 15.10. Market Attractiveness Analysis
  • 15.10.1. By Country
  • 15.10.2. By Drug Class
  • 15.10.3. By Indication
  • 15.10.4. By Distributional Channel
• 15.11. Drivers and Restraints: Impact Analysis

16. Europe Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
  • 16.2.1. Germany
  • 16.2.2. Italy
  • 16.2.3. France
  • 16.2.4. U.K.
  • 16.2.5. Spain
  • 16.2.6. BENELUX
  • 16.2.7. Russia
  • 16.2.8. Rest of Europe
• 16.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 16.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 16.4.1. Anti-VEGF
  • 16.4.2. Corticosteriods
  • 16.4.3. Antibiotics
  • 16.4.4. Antivirals
  • 16.4.5. Antifungals
• 16.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 16.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 16.6.1. Diabetic Retinopathy
  • 16.6.2. Macular Degeneration
  • 16.6.3. Endophthalmitis
  • 16.6.4. Retinal Vein Occlusion
  • 16.6.5. Others
• 16.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 16.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 16.8.1. Hospital Pharmacies
  • 16.8.2. Retail Pharmacies
  • 16.8.3. Drug Stores
  • 16.8.4. Mail Order Pharmacies
  • 16.8.5. Others
• 16.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 16.10. Market Attractiveness Analysis
  • 16.10.1. By Country
  • 16.10.2. By Drug Class
  • 16.10.3. By Indication
  • 16.10.4. By Distributional Channel
• 16.11. Drivers and Restraints: Impact Analysis

17. South Asia Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
  • 17.2.1. India
  • 17.2.2. Thailand
  • 17.2.3. Indonesia
  • 17.2.4. Malaysia
  • 17.2.5. Rest of South Asia
• 17.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 17.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 17.4.1. Anti-VEGF
  • 17.4.2. Corticosteriods
  • 17.4.3. Antibiotics
  • 17.4.4. Antivirals
  • 17.4.5. Antifungals
• 17.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 17.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 17.6.1. Diabetic Retinopathy
  • 17.6.2. Macular Degeneration
  • 17.6.3. Endophthalmitis
  • 17.6.4. Retinal Vein Occlusion
  • 17.6.5. Others
• 17.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 17.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 17.8.1. Hospital Pharmacies
  • 17.8.2. Retail Pharmacies
  • 17.8.3. Drug Stores
  • 17.8.4. Mail Order Pharmacies
  • 17.8.5. Others
• 17.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 17.10. Market Attractiveness Analysis
  • 17.10.1. By Country
  • 17.10.2. By Drug Class
  • 17.10.3. By Indication
  • 17.10.4. By Distributional Channel
• 17.11. Drivers and Restraints: Impact Analysis

18. East Asia Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
  • 18.2.1. China
  • 18.2.2. Japan
  • 18.2.3. South Korea
• 18.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 18.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 18.4.1. Anti-VEGF
  • 18.4.2. Corticosteriods
  • 18.4.3. Antibiotics
  • 18.4.4. Antivirals
  • 18.4.5. Antifungals
• 18.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 18.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 18.6.1. Diabetic Retinopathy
  • 18.6.2. Macular Degeneration
  • 18.6.3. Endophthalmitis
  • 18.6.4. Retinal Vein Occlusion
  • 18.6.5. Others
• 18.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 18.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 18.8.1. Hospital Pharmacies
  • 18.8.2. Retail Pharmacies
  • 18.8.3. Drug Stores
  • 18.8.4. Mail Order Pharmacies
  • 18.8.5. Others
• 18.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 18.10. Market Attractiveness Analysis
  • 18.10.1. By Country
  • 18.10.2. By Drug Class
  • 18.10.3. By Indication
  • 18.10.4. By Distributional Channel
• 18.11. Drivers and Restraints: Impact Analysis

19. Oceania Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
  • 19.2.1. Australia
  • 19.2.2. New Zealand
• 19.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 19.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 19.4.1. Anti-VEGF
  • 19.4.2. Corticosteriods
  • 19.4.3. Antibiotics
  • 19.4.4. Antivirals
  • 19.4.5. Antifungals
• 19.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 19.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 19.6.1. Diabetic Retinopathy
  • 19.6.2. Macular Degeneration
  • 19.6.3. Endophthalmitis
  • 19.6.4. Retinal Vein Occlusion
  • 19.6.5. Others
• 19.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 19.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 19.8.1. Hospital Pharmacies
  • 19.8.2. Retail Pharmacies
  • 19.8.3. Drug Stores
  • 19.8.4. Mail Order Pharmacies
  • 19.8.5. Others
• 19.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 19.10. Market Attractiveness Analysis
  • 19.10.1. By Country
  • 19.10.2. By Drug Class
  • 19.10.3. By Indication
  • 19.10.4. By Distributional Channel
• 19.11. Drivers and Restraints: Impact Analysis

20. Middle East and Africa Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 20.1. Introduction
• 20.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
  • 20.2.1. GCC Countries
  • 20.2.2. Turkey
  • 20.2.3. Northern Africa
  • 20.2.4. South Africa
  • 20.2.5. Rest of Middle East and Africa
• 20.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
• 20.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 20.4.1. Anti-VEGF
  • 20.4.2. Corticosteriods
  • 20.4.3. Antibiotics
  • 20.4.4. Antivirals
  • 20.4.5. Antifungals
• 20.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 20.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 20.6.1. Diabetic Retinopathy
  • 20.6.2. Macular Degeneration
  • 20.6.3. Endophthalmitis
  • 20.6.4. Retinal Vein Occlusion
  • 20.6.5. Others
• 20.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 20.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 20.8.1. Hospital Pharmacies
  • 20.8.2. Retail Pharmacies
  • 20.8.3. Drug Stores
  • 20.8.4. Mail Order Pharmacies
  • 20.8.5. Others
• 20.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 20.10. Market Attractiveness Analysis
  • 20.10.1. By Country
  • 20.10.2. By Drug Class
  • 20.10.3. By Indication
  • 20.10.4. By Distributional Channel
• 20.11. Drivers and Restraints: Impact Analysis

21. Emerging Countries Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

• 21.1. Introduction
• 21.2. Global Vs. Country Growth Comparison

22. China Intravitreal Injectables (IVT) Market Analysis 2019-2023 and Forecast 2024-2031

• 22.1. Introduction
• 22.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 22.2.1. Anti-VEGF
  • 22.2.2. Corticosteriods
  • 22.2.3. Antibiotics
  • 22.2.4. Antivirals
  • 22.2.5. Antifungals
  • 22.2.6. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 22.3. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 22.3.1. Diabetic Retinopathy
  • 22.3.2. Macular Degeneration
  • 22.3.3. Endophthalmitis
  • 22.3.4. Retinal Vein Occlusion
  • 22.3.5. Others
• 22.4. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 22.5. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 22.5.1. Hospital Pharmacies
  • 22.5.2. Retail Pharmacies
  • 22.5.3. Drug Stores
  • 22.5.4. Mail Order Pharmacies
  • 22.5.5. Others
• 22.6. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 22.7. Market Attractiveness Analysis
  • 22.7.1. By Country
  • 22.7.2. By Drug Class
  • 22.7.3. By Indication
  • 22.7.4. By Distributional Channel
• 22.8. PESTLE Analysis
• 22.9. Drivers and Restraints: Impact Analysis

23. India Intravitreal Injectables (IVT) Market Analysis 2019-2023 and Forecast 2024-2031

• 23.1. Introduction
• 23.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 23.2.1. Anti-VEGF
  • 23.2.2. Corticosteriods
  • 23.2.3. Antibiotics
  • 23.2.4. Antivirals
  • 23.2.5. Antifungals
• 23.3. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 23.4. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 23.4.1. Diabetic Retinopathy
  • 23.4.2. Macular Degeneration
  • 23.4.3. Endophthalmitis
  • 23.4.4. Retinal Vein Occlusion
  • 23.4.5. Others
• 23.5. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 23.6. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 23.6.1. Hospital Pharmacies
  • 23.6.2. Retail Pharmacies
  • 23.6.3. Drug Stores
  • 23.6.4. Mail Order Pharmacies
  • 23.6.5. Others
• 23.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 23.8. Market Attractiveness Analysis
  • 23.8.1. By Country
  • 23.8.2. By Drug Class
  • 23.8.3. By Indication
  • 23.8.4. By Distributional Channel
• 23.9. PESTLE Analysis
• 23.10. Drivers and Restraints: Impact Analysis

24. Mexico Intravitreal Injectables (IVT) Market Analysis 2019-2023 and Forecast 2024-2031

• 24.1. Introduction
• 24.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
  • 24.2.1. Anti-VEGF
  • 24.2.2. Corticosteriods
  • 24.2.3. Antibiotics
  • 24.2.4. Antivirals
  • 24.2.5. Antifungals
• 24.3. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
• 24.4. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
  • 24.4.1. Diabetic Retinopathy
  • 24.4.2. Macular Degeneration
  • 24.4.3. Endophthalmitis
  • 24.4.4. Retinal Vein Occlusion
  • 24.4.5. Others
• 24.5. Market Size (US$ Mn) Forecast By Indication, 2024-2031
• 24.6. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
  • 24.6.1. Hospital Pharmacies
  • 24.6.2. Retail Pharmacies
  • 24.6.3. Drug Stores
  • 24.6.4. Mail Order Pharmacies
  • 24.6.5. Others
• 24.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
• 24.8. Market Attractiveness Analysis
  • 24.8.1. By Country
  • 24.8.2. By Drug Class
  • 24.8.3. By Indication
  • 24.8.4. By Distributional Channel
• 24.9. PESTLE Analysis
• 24.10. Drivers and Restraints: Impact Analysis

25. Forecast Factors: Relevance and Impact

26. Forecast Assumptions

27. Competition Analysis

• 27.1. Competition Dashboard
• 27.2. Competition Deep Dive
  • 27.2.1. F. Hoffmann-La Roche Ltd
    • 27.2.1.1. Overview
    • 27.2.1.2. Key Financials
    • 27.2.1.3. SWOT Analysis
    • 27.2.1.4. Key Developments
    • 27.2.1.5. Key Strategy
  • 27.2.2. Regeneron Pharmaceuticals, Inc.
    • 27.2.2.1. Overview
    • 27.2.2.2. Key Financials
    • 27.2.2.3. SWOT Analysis
    • 27.2.2.4. Key Developments
    • 27.2.2.5. Key Strategy
  • 27.2.3. Bausch & Lomb
    • 27.2.3.1. Overview
    • 27.2.3.2. Key Financials
    • 27.2.3.3. SWOT Analysis
    • 27.2.3.4. Key Developments
    • 27.2.3.5. Key Strategy
  • 27.2.4. Novartis AG
    • 27.2.4.1. Overview
    • 27.2.4.2. Key Financials
    • 27.2.4.3. SWOT Analysis
    • 27.2.4.4. Key Developments
    • 27.2.4.5. Key Strategy
  • 27.2.5. Allergan
    • 27.2.5.1. Overview
    • 27.2.5.2. Key Financials
    • 27.2.5.3. SWOT Analysis
    • 27.2.5.4. Key Developments
    • 27.2.5.5. Key Strategy
  • 27.2.6. Alimera Sciences
    • 27.2.6.1. Overview
    • 27.2.6.2. Key Financials
    • 27.2.6.3. SWOT Analysis
    • 27.2.6.4. Key Developments
    • 27.2.6.5. Key Strategy
  • 27.2.7. ThromboGenics, Inc.
    • 27.2.7.1. Overview
    • 27.2.7.2. Key Financials
    • 27.2.7.3. SWOT Analysis
    • 27.2.7.4. Key Developments
    • 27.2.7.5. Key Strategy
  • 27.2.8. Bristol-Myers Squibb Company
    • 27.2.8.1. Overview
    • 27.2.8.2. Key Financials
    • 27.2.8.3. SWOT Analysis
    • 27.2.8.4. Key Developments
    • 27.2.8.5. Key Strategy

28. Assumptions and Acronyms Used

29. Research Methodology